145 related articles for article (PubMed ID: 23732458)
1. Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.
Jha V; Modi GK
Nat Rev Nephrol; 2013 Jul; 9(7):377-9. PubMed ID: 23732458
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
[TBL] [Abstract][Full Text] [Related]
4. Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Hickman J
Br J Gen Pract; 2010 Jan; 60(570):50-2. PubMed ID: 20040169
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin and coronary heart disease.
Bloom JM
N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
Ganz DA; Kuntz KM; Jacobson GA; Avorn J
Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
[TBL] [Abstract][Full Text] [Related]
7. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
8. Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?
Mahoney EM
Circulation; 2010 Oct; 122(15):1446-8. PubMed ID: 20876432
[No Abstract] [Full Text] [Related]
9. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
10. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
11. [Statines for all or individualized lipid lowering therapy?].
Parhofer K
MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
[No Abstract] [Full Text] [Related]
12. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
[TBL] [Abstract][Full Text] [Related]
15. [Stroke, cholesterol and statins--are there new data about stroke prevention?].
Ferbert A
Dtsch Med Wochenschr; 2001 Jun; 126(22):664-70. PubMed ID: 11450627
[No Abstract] [Full Text] [Related]
16. Pravastatin and cardiovascular risk in moderate chronic kidney disease.
Nakamura H; Mizuno K; Ohashi Y; Yoshida T; Hirao K; Uchida Y;
Atherosclerosis; 2009 Oct; 206(2):512-7. PubMed ID: 19423108
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
Tonelli M; Moyé L; Sacks FM; Cole T; Curhan GC;
J Am Soc Nephrol; 2003 Jun; 14(6):1605-13. PubMed ID: 12761262
[TBL] [Abstract][Full Text] [Related]
18. Statins for everyone--(even for those at low risk.) Experts are excited, but the question is whether benefits would outweigh costs.
Duke Med Health News; 2009 Feb; 15(2):1, 11. PubMed ID: 19358321
[No Abstract] [Full Text] [Related]
19. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
Greving JP; Visseren FL; de Wit GA; Algra A
BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]